Immunogenicity and Safety of a Chemically Synthesized Divalent Group A Streptococcal Vaccine

Yongxiang Wu, Suhua Li, Yanting Luo, Yunyue Zhao, Jiarui Wang, Ruimin Dong, Xujing Xie, Jieming Zhu, Jinlai LiuCanadian 2018 · DOI

TL;DR

This paper presents a promising new divalent vaccine against Group A Streptococcus (GAS), targeting the prevalent M1 and M12 serotypes in China. The chemically synthesized peptide vaccine demonstrated strong immunogenicity, induced protective antibodies, and significantly improved survival rates in mice challenged with GAS, all without apparent autoimmune side effects.

What Problem Does This Paper Address?

Group A Streptococcus (GAS) infections are a significant global health concern, causing a range of diseases from mild pharyngitis to life-threatening conditions like toxic shock syndrome and necrotizing fasciitis. Furthermore, GAS infections can lead to severe autoimmune sequelae such as rheumatic fever and rheumatic heart disease, particularly in developing countries with limited healthcare access. Despite decades of research, no licensed GAS vaccine is currently available. A major hurdle in vaccine development is the vast diversity of GAS serotypes, with over 200 identified emm types. Immunity to one serotype does not confer protection against others, making broad coverage challenging. Existing multivalent vaccines have shown limited efficacy in certain regions due to the uneven distribution of serotypes. This study aims to address this by developing a geographically targeted vaccine, focusing on the most prevalent serotypes in China (M1 and M12), and evaluating its immunogenicity and safety.

Methods

The researchers developed a chemically synthesized divalent peptide vaccine composed of 84 amino acids. This vaccine includes a 35-amino acid sequence from the N-terminus of the M1 protein, a 35-amino acid sequence from the N-terminus of the M12 protein, and a 14-amino acid sequence (J14 peptide) from the conserved C-terminus of both M proteins.

To assess immunogenicity, female BALB/c mice were immunized with the peptide vaccine emulsified in Freund's adjuvant, followed by booster shots. Serum antibody titers were measured using Enzyme-Linked Immunosorbent Assay (ELISA). The functional activity of these antibodies was evaluated through indirect bactericidal assays, which measured the reduction in viable GAS colony-forming units (CFUs) in the presence of the antisera. Immunofluorescence assays were used to visualize antibody binding to the surface of GAS bacteria.

The protective efficacy of the vaccine was tested by challenging immunized and control mice with live M1 and M12 GAS strains and monitoring survival rates. Safety was assessed through histopathological analysis of various organs from mice that received high-dose immunization, looking for signs of autoimmune reactions.

Datasets

Not discussed in the paper. The study utilized emm1 and emm12 GAS strains isolated from human tonsil or throat samples, identified and preserved in their laboratory.

Key Insights and Ideas

  • Targeted Approach for Regional Efficacy: The study highlights the feasibility of developing region-specific GAS vaccines by focusing on dominant serotypes, a strategy that could be more effective than broad-spectrum vaccines in diverse geographical areas.
  • Chemical Synthesis Advantage: The use of chemical synthesis for the peptide vaccine offers a potentially faster and more scalable production method compared to molecular cloning techniques used in previous research.
  • Dual N-terminal Epitope Strategy: Combining epitopes from the highly variable N-termini of M1 and M12 proteins, along with a conserved C-terminal peptide, aims to elicit both type-specific and potentially broader protective responses.
  • Safety Without Autoimmunity: A critical finding is the absence of autoimmune reactions in mice, a significant concern for M protein-based vaccines, suggesting this approach may mitigate such risks.

Key Results

  • High Antibody Titers: Immunized mice developed significantly higher antibody titers against the vaccine, M1 peptide, M12 peptide, and J14 peptide compared to control mice.
  • Bactericidal Activity: Antisera from immunized mice demonstrated significant opsonic activity, leading to a 93.1% decrease in M1 GAS CFU and an 89.5% decrease in M12 GAS CFU.
  • Antibody Binding: Immunofluorescence confirmed that antibodies from immunized mice bound to the surface of both M1 and M12 GAS strains.
  • Protection Against Challenge: Immunized mice showed significantly higher survival rates when challenged with M1 GAS (87.5% vs. 37.5% in controls) and M12 GAS (75% vs. 25% in controls).
  • No Autoimmune Reactions: Histopathological examination of organs from immunized mice revealed no signs of autoimmune reactions or other pathological lesions.

Limitations and Future Work

The authors acknowledge that a limitation is the inability to test the vaccine's cross-reactivity with human tissues directly, although they designed the peptide sequences to minimize the possibility of cross-reactivity with human proteins. They also note that while this vaccine is tailored for China, the global diversity of GAS serotypes means that a universally effective vaccine remains a challenge.

Future work will involve advancing this chemically synthesized divalent vaccine into clinical trials. The researchers also suggest that this strategy of developing geographically region-specific multivalent vaccines based on dominant serotypes could be extended to other regions with different prevalent GAS strains.

Summary updated

Abstract

The results suggest that this vaccine shows fair immunogenicity and safety, which will lead our research on GAS vaccine into clinical trial.
BibTeX
@inproceedings{wu2018immunogenicity,
  author = {Yongxiang Wu and Suhua Li and Yanting Luo and Yunyue Zhao and Jiarui Wang and Ruimin Dong and Xujing Xie and Jieming Zhu and Jinlai Liu},
  title = {{Immunogenicity and Safety of a Chemically Synthesized Divalent Group A Streptococcal Vaccine}},
  booktitle = {Canadian},
  year = {2018},
  doi = {10.1155/2018/4702152},
}
Figure